Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:17 PM ET 8-K
Nasdaq/NYSE Compliance Notice Hain Celestial Group Inc HAIN

Hain Celestial Group Nasdaq/NYSE Compliance Notice

Hain Celestial received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to March 22, 2027. To facilitate this, the company transferred its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. Separately, the company announced that Chief Accounting Officer Michael J. Ragusa will resign effective November 1, 2026.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
4:13 PM ET 8-K
Capital Raise Eagle Point Trinity Senior Secured Lending Co

Eagle Point Trinity Senior Secured Lending Capital Raise

Eagle Point Trinity Senior Secured Lending Company issued and sold 910.51 common shares for aggregate proceeds of $9,325. The private placement was conducted via subscription agreements and the share count was finalized on September 22, 2026.

4:12 PM ET 8-K
M&A Deal Peoples Bancorp Inc PEBO

Peoples Bancorp M&A Deal with Citizens National Corporation

Peoples Bancorp Inc. has received all necessary regulatory approvals for its pending acquisition of Citizens National Corporation and its subsidiary, Citizens Bank of Kentucky. The merger agreement, originally dated April 20, 2026, was previously approved by Citizens' shareholders in August 2026. This update confirms the removal of regulatory hurdles for the transaction, which will see Peoples as the surviving corporation.

Counterparty
Citizens National Corporation
4:09 PM ET 8-K
M&A Deal Kimberly Clark Corp KMB

Kimberly Clark Signs $7B M&A Deal with Kenvue Inc.

Kimberly-Clark announced a $7.0 billion exchange offer and consent solicitation for Kenvue Inc. notes as part of its pending acquisition of the company. The exchange offer allows holders of Kenvue notes to swap them for new Kimberly-Clark notes and cash, contingent on the merger closing which is expected in Q4 2026.

Value
$7B
Counterparty
Kenvue Inc.
4:06 PM ET 8-K
Research Collaboration Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M

Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.

Value
$5M
Counterparty
Factor Bioscience Inc.
Term
annual
4:06 PM ET 8-K
M&A Deal Beazer Homes USA Inc BZH

Beazer Homes USA Signs $350M M&A Deal with Dream Finders Homes, Inc.

Beazer Homes USA issued a conditional notice to redeem $350.0 million of its 7.250% Senior Notes due 2029. The redemption is contingent upon the closing of its previously announced merger with Dream Finders Homes, Inc., which is expected to occur on October 20, 2026. This filing provides a status and timeline update on the pending acquisition of Beazer Homes by Dream Finders Homes.

Value
$350M
Counterparty
Dream Finders Homes, Inc.
4:05 PM ET 8-K
Capital Raise Grayscale Bittensor Trust (TAO) GTAO

Grayscale Bittensor Trust Capital Raise of $891K

Grayscale Bittensor Trust (TAO) issued 151,900 shares in private placement transactions to accredited investors, raising approximately $0.89 million. The shares were issued at varying prices based on the Trust's Net Asset Value (NAV) per share in exchange for 2,869.42 TAO tokens. As of September 28, 2026, the Trust has a total of 2,994,200 shares issued and outstanding.

Value
$891K
Counterparty
Accredited investors
4:03 PM ET 8-K
M&A Deal iQSTEL Inc IQST

iQSTEL Signs $500K M&A Deal with Craig Span

iQSTEL Inc. entered into an amendment to its acquisition agreement for GlobeTopper, LLC to settle a $500,000 purchase price obligation in cash rather than restricted common stock. The payment will be made in installments through early 2027 and is secured by the 51% membership interest in GlobeTopper originally acquired in 2025.

Value
$500K
Counterparty
Craig Span
4:02 PM ET 8-K
Contract Win Scynexis Inc SCYX

Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority

SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.

Value
$214M
Counterparty
Biomedical Advanced Research and Development Authority (BARDA)
Term
up to 10 years

“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS

“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
4:02 PM ET 8-K
Nasdaq/NYSE Compliance Notice Gossamer Bio, Inc. GOSS

Gossamer Bio Nasdaq/NYSE Compliance Notice

Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.

Counterparty
The Nasdaq Stock Market LLC
4:02 PM ET 8-K
Capital Raise ADARx Pharmaceuticals, Inc. ADRX

ADARx Pharmaceuticals Capital Raise of $536M

ADARx Pharmaceuticals closed its initial public offering (IPO) of 26,250,000 shares and a concurrent private placement of 5,255,542 shares to AbbVie Inc., both priced at $17.00 per share. The combined transactions generated approximately $535.6 million in gross proceeds, with AbbVie acquiring a 4.9% stake in the company.

Value
$536M
Counterparty
AbbVie Inc.
1:20 PM ET 8-K/A
M&A Deal Exascale Labs Holdings Inc. XLAB

Exascale Labs Holdings M&A Deal with Exascale Labs Inc.

Exascale Labs Holdings Inc. (formerly D. Boral ARC Merger Corporation) filed this amendment to provide required financial statements following the completion of its business combination with Exascale Labs Inc. The merger was consummated on August 27, 2026, resulting in Exascale Labs Inc. becoming a subsidiary of the public entity. This filing includes audited financial statements for Exascale Labs for the fiscal years ended June 30, 2026 and 2025.

Counterparty
Exascale Labs Inc.
1:07 PM ET 8-K
M&A Deal Marygold Companies, Inc. MGLD

Marygold Companies M&A Deal with Madison Dearborn Partners, LLC

The Marygold Companies (MGLD) entered into a definitive agreement to be acquired by funds managed by Madison Dearborn Partners (MDP) for $2.00 per share in cash. The transaction, which represents a 100% premium over the company's unaffected closing price, will result in Marygold becoming a privately held company. Following the merger, MDP plans to refocus the business on its USCF subsidiary, a commodity-focused ETF manager with approximately $6 billion in assets under management.

Counterparty
Madison Dearborn Partners, LLC
11:32 AM ET 8-K
M&A Deal Coastal Financial Corp CCB

Coastal Financial M&A Deal with Bluevine, Inc.

Coastal Financial Corporation's fintech partner, Bluevine, Inc., has entered into a definitive agreement to be acquired by Valley National Bancorp. Coastal Community Bank currently holds approximately $447 million in Bluevine-related deposits, but management does not expect the transaction to have a material adverse effect on the company's liquidity or funding profile due to its diversified partner platform.

Counterparty
Bluevine, Inc.
11:08 AM ET 8-K
Regulatory Approval CapsoVision, Inc CV

CapsoVision Regulatory Approval

CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.

10:49 AM ET 8-K
M&A Deal Portland General Electric Co POR

Portland General Electric Signs $83M M&A Deal with Oregon Public Utility Commission

Portland General Electric (PGE) received a final order from the Oregon Public Utility Commission regarding its proposed reorganization into a holding company structure. While the order includes $83 million in customer benefits, it imposes restrictive conditions on dividends and credit ratings that PGE claims may prevent the reorganization from proceeding. The company is currently evaluating legal options, including judicial review, and does not expect to move forward with the deal unless the provisions are modified.

Value
$83M
Counterparty
Oregon Public Utility Commission (OPUC)
9:27 AM ET 8-K
M&A Deal Proem Acquisition Corp. I PAAC

Proem Acquisition Corp. I Signs $50M M&A Deal with Astro Digital US, Inc.

Proem Acquisition Corp I (PAAC), a SPAC, has entered into a definitive merger agreement to acquire Astro Digital US, Inc., a satellite technology infrastructure company. The transaction includes a $50 million PIPE investment co-led by Proem Asset Management and Leon Capital Group, with the combined company expected to trade on Nasdaq under the name Astro Digital Holdings, Inc. in Q1 2027.

Value
$50M
Counterparty
Astro Digital US, Inc.
Earnings call
Sep 28, 2026, 9:00 AM ET
9:23 AM ET 8-K
M&A Deal Columbus Acquisition Corp COLAU

Columbus Acquisition M&A Deal with WISeSat.Space Corp

Columbus Acquisition Corp has adjourned its Extraordinary General Meeting of Shareholders to September 29, 2026, without conducting any business. The meeting is intended to vote on the proposed business combination with WISeSat.Space Corp. This represents a status update on a pending merger for the SPAC.

Counterparty
WISeSat.Space Corp
9:11 AM ET 8-K
Divestiture Greenpro Capital Corp. GRNQ

Greenpro Capital Divestiture to Ms. Chen Yanhong

Greenpro Capital Corp. completed the sale of its F&A Entities, including Greenpro Resources (HK) Limited and several other subsidiaries, to Ms. Chen Yanhong for approximately $0.45 million in cash. The divested entities primarily provided corporate advisory and company-secretarial services in Hong Kong and China. The company plans to use the proceeds for general corporate purposes and will report these entities as discontinued operations starting in Q3 2026.

Counterparty
Ms. Chen Yanhong
9:02 AM ET 8-K
M&A Deal Getty Realty Corp GTY

Getty Realty Signs $261M M&A Deal with Refuel Operating Company, LLC

Getty Realty Corp. acquired a portfolio of 41 convenience store properties from Refuel Operating Company for $260.9 million in a sale-leaseback transaction. The properties, located across four states, were simultaneously leased back to Refuel under four unitary triple net leases with initial 20-year terms. The acquisition was funded through forward equity proceeds, unsecured debt, and property dispositions.

Value
$261M
Counterparty
Refuel Operating Company, LLC
Term
20 years
8:54 AM ET 8-K
Clinical Trial Data Kodiak Sciences Inc. KOD

Kodiak Sciences Clinical Trial Data

Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.

8:54 AM ET 8-K
M&A Deal Lifecore Biomedical, Inc. \De\ LFCR

Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners

Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.

Value
$664M
Counterparty
Webster Equity Partners
8:47 AM ET 8-K
Clinical Trial Data Silexion Therapeutics Corp SLXN

Silexion Therapeutics Clinical Trial Data

Silexion Therapeutics announced positive preclinical translational research findings for its lead RNAi candidate, SIL204, demonstrating a mechanism for systemic uptake in KRAS-driven cancers. The study showed that SIL204 utilizes native serum lipids and lipoprotein pathways for cellular entry and gene silencing without the need for artificial nanoparticles, supporting its upcoming Phase 2/3 clinical program.

8:32 AM ET 8-K
M&A Deal Silicon Valley Acquisition Corp. SVAQ

Silicon Valley Acquisition M&A Deal with EigenQ, Inc.

Silicon Valley Acquisition Corp. (SVAQ) entered into a third amendment to its definitive business combination agreement with EigenQ, Inc. The amendment modifies the treatment of certain EigenQ warrants, clarifying they will be exchanged for PubCo warrants upon the closing of the merger. This filing provides a status update on the pending SPAC merger which will result in EigenQ becoming a wholly owned subsidiary of the domesticated Delaware corporation.

Counterparty
EigenQ, Inc.
8:17 AM ET 8-K
M&A Deal Bold Eagle Acquisition Corp. BEAG

Bold Eagle Acquisition Signs $1.25B M&A Deal with REDLattice

Bold Eagle Acquisition Corp. (BEAG) has entered into a definitive business combination agreement to acquire REDLattice, a cyber intelligence platform for defense and national security, at a pre-money enterprise value of $1.25 billion. The transaction is supported by $335 million in committed capital, including a $60 million common stock investment, and will result in REDLattice becoming a publicly traded company on the Nasdaq under the ticker 'REDL'.

Value
$1.25B
Counterparty
REDLattice (REDL Intermediate Holdings, LLC)
8:17 AM ET 8-K
Clinical Trial Data Transcode Therapeutics, Inc. RNAZ

Transcode Therapeutics Clinical Trial Data

TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.

8:16 AM ET 8-K
Clinical Trial Data Adicet Bio, Inc. ACET

Adicet Bio Clinical Trial Data

Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.

Earnings call
Sep 28, 2026, 8:00 AM ET
8:06 AM ET 8-K
Contract Win Volato Group, Inc. SOAR

Volato Group Wins $1.17B Contract from a large AI customer

Volato Group's subsidiary, Alignment Engine, signed a Master Services Agreement and two initial orders with a large AI customer for dedicated AMD GPU infrastructure in Ohio. The aggregate contract value is approximately $1.17 billion over a four-year take-or-pay term, including $133 million in contractual prepayments. This represents a transformational milestone for the company's AI infrastructure platform.

Value
$1.17B
Counterparty
a large AI customer
Term
48-month term
8:06 AM ET 8-K
Clinical Trial Data 4D Molecular Therapeutics, Inc. FDMT

4D Molecular Therapeutics Clinical Trial Data

4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.

8:04 AM ET 8-K
Regulatory Approval Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.